Treatment of lentigo maligna with tazarotene 0.1% gel

J Am Acad Dermatol. 2004 Jan;50(1):101-3. doi: 10.1016/j.jaad.2003.07.005.

Abstract

We report 2 elderly patients with facial lentigo maligna who experienced complete regression, both clinically and histopathologically, after once-daily topical treatment with tazarotene 0.1% gel for 6 to 8 months. After a follow-up period of 18 and 30 months, no recurrence was observed. We believe that tazarotene might be considered as an alternative medical approach in selected patients with lentigo maligna.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Aged, 80 and over
  • Dermatologic Agents / administration & dosage*
  • Female
  • Gels
  • Humans
  • Hutchinson's Melanotic Freckle / drug therapy*
  • Male
  • Nicotinic Acids / administration & dosage*

Substances

  • Dermatologic Agents
  • Gels
  • Nicotinic Acids
  • tazarotene